Overview

Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

Status:
Completed

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

This study will assess the effectiveness of solifenacin succinate (VESIcare) in reducing symptoms of overactive bladder in Parkinson's disease (PD) patients.

Phase:

Phase 4

Details

Lead Sponsor:

University of South Florida

Treatments:

Solifenacin Succinate